Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose. The phase II clinical trial evaluating the effect of different doses of the novel glucagon/GLP-1 receptor dual agonist BI 456906 in people living with obesity or overweight without type 2 diabetes (NCT04667377) met its primary endpoint. These results including an analysis of the actual maintenance dose indicating even greater weight loss will be presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S. Until then, the data is under embargo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005447/en/
“Obesity is one of many cardio-renal-metabolic diseases, which together represent one of the fastest growing health challenges worldwide. The distinct mode of action of BI 456906 targets multiple pathways pivotal to metabolic regulation, including those associated with obesity and liver diseases,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. “With our longstanding heritage in cardio-renal-metabolic diseases, we are excited by the findings and potential implications for millions of people who urgently need healthcare solutions.”
“We are both enthusiastic about these data and encouraged by the clinical outcomes announced today,” said David Kendall, M.D., Chief Medical Officer, Zealand Pharma. “At Zealand Pharma we continue our long-term commitment to the discovery and development of novel differentiated peptide therapeutics that target critical metabolic pathways to achieve substantial weight loss while addressing the complex pathophysiology of overweight and obesity.”
In 2016, more than 1 billion people worldwide were living with cardio-renal-metabolic (CRM) diseases such as obesity, type 2 diabetes, chronic kidney disease, liver disease, heart failure and cardiovascular disease1-10. Obesity is a major global health challenge, and the worldwide prevalence has more than doubled over the past four decades11. The World Obesity Federation predicts that by 2025, 2.7 billion adults could be living with obesity or overweight, placing a high burden on individuals, healthcare systems and society11.
Notes to editors
Please click on the following link for ‘Notes to editors’ and ‘References’
https://www.boehringer-ingelheim.com/phase-ll-trial-results-in-obesity-or-overweight
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005447/en/
Contact information
Harro ten Wolde
Global Head of Media Relations
Boehringer Ingelheim
Email: harro.ten_wolde@boehringer-ingelheim.com
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MSCI to Consult on a Potential Reclassification of Greece to Developed Market status27.1.2026 01:15:00 EET | Press release
MSCI Inc. (NYSE: MSCI) announced today the launch of a consultation on a proposal for the potential reclassification of Greece from Emerging Market status to Developed Market status in one step, with implementation targeted for the August 2026 Index Review. As part of the MSCI 2025 Market Classification Review, MSCI acknowledged that the Greek market made progress in aligning with the accessibility standards commonly observed in Developed Markets in Europe and that Greece also meets the Economic Development criteria for Developed Market status. However, at the time, Greece did not meet the Size and Liquidity persistency rule, which requires a minimum number of five companies to meet Developed Market Standard Index criteria over each of the last eight Index Reviews to consider an upward reclassification. MSCI treats European countries classified as Developed Markets as a single entity for index construction and maintenance purposes. This approach reflects the high degree of integration
The World’s Most Romantic Building: ESB Celebrates Valentine’s Day 2026 with NYC's Most Extravagant Date Night, Romantic Paint ‘ n Pour Classes, ‘Sleepless in Seattle’ Screenings, Proposal Package, and More27.1.2026 01:14:00 EET | Press release
Love is in the air at the “World’s Most Romantic Building.” The Empire State Building (ESB) today announced its romantic Valentine’s Day plans for couples in NYC, which include an over-the-top date night, Paint ‘n Pour classes, romantic movie screenings, a sunrise experience, and more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126953627/en/ The World’s Most Romantic Building: ESB Celebrates Valentine’s Day 2026 with NYC's Most Extravagant Date Night, Romantic Paint ‘n Pour Classes, ‘Sleepless in Seattle’ Screenings, Proposal Package, and More “The Empire State Building Observation Deck has played a role in countless love stories throughout its 95-year history, from Hollywood movies to first dates and proposals,” said Dan Rogoski, observatory general manager. “Our world-famous Observatory Experience is the top NYC attraction for couples to make unforgettable memories on Valentine’s Day.” Empire for Two: For the third
Rimini Street to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 19, 202626.1.2026 20:46:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on February 19, 2026. The company will host a conference call and webcast on that date to discuss the fourth quarter and fiscal year 2025 results and the 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126188817/en/ Rimini Street to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 19, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, In
SES Acknowledges Fitch’s Rating Action and Reiterates Deleveraging Plan26.1.2026 20:07:00 EET | Press release
SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Fitch today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES continues to be rated investment grade by Fitch with a stable outlook. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. The Company also has a clear view of the multiple cash generating levers available to it that it believes can substantially support and accelerate the deleveraging plan. SES management will use these levers in a disciplined way and keep investors informed as they deliver on the strategic plan. Consistent with this plan, it remains management’s intention to delever, with a policy objective of reducing adjusted net leverage(1) to at least 3.0x or below. (1) Adjusted net leverage is defined as Adjusted Net Debt divided by Adjusted EBITDA. Adjusted Net Debt is
A2RL Drone Championship Sets the Pace for AI in Autonomous Flight26.1.2026 19:17:00 EET | Press release
The Abu Dhabi Autonomous Racing League (A2RL) Drone Championship delivered a decisive test of autonomous and human performance, as Technology Innovation Institute’s TII Racing set the fastest autonomous lap to win the AI Speed Challenge, while a human first-person-view (FPV) pilot, MinChan Kim – World FPV Champion, narrowly claimed victory in the Human vs AI finale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126735530/en/ A2RL Drone Championship Sets the Pace for AI in Autonomous Flight (Photo: AETOSWire) Organised by ASPIRE, the innovation acceleration arm of the Advanced Technology Research Council (ATRC), the event highlighted both the rapid progress of vision-based autonomy and the narrow margins that still separate human instinct from machine execution at speed. Held over two days on 21–22 January during UMEX, the A2RL Championship brought together leading AI research teams and world-class FPV pilots to compete a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom